The World Health Organisation will held the 130th meeting of its Executive Board from 16 to 23 January 2012.
The agenda of the session contains a number of very important issues, some of which are of particular relevance for health innovation:
- 6.13 Substandard/spurious/falsely-labelled/falsified/counterfeit medical products: report of the Working Group of Member States
Other agenda items to be noted include:
- 6.1 Prevention and control of noncommunicable diseases
- 6.5 Monitoring of the achievement of the health-related Millennium Development Goals: Progress in the achievement of the health-related Millennium Development Goals; Global health goals after 2015.
- 6.6 Social determinants of health: outcome of the World Conference on Social Determinants of Health (Rio de Janeiro, Brazil, October 2011)
- 6.9 Pandemic Influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the work of the Advisory Group
- 6.12 Draft global vaccine action plan: update
Needs-driven innovation for health can in no way ignore the role of WHO. This is why HIP has actively embarked on monitoring the WHO reform process . Issues to be considered by the Executive Board include those of governance, management, financing, relationship with other stakeholders and evaluation, including proposals for a two-stage independent evaluation of WHO to inform the reform process. Following the Decisions of the Executive Board Special Session of November 2011, the WHO Secretariat has produced several documents on these issues, containing various concrete proposals.
Finally, if time permits, the Members of the Executive Board should be invited to consider several progress reports, including on Health systems and research, specifically: Health system strengthening (resolutions WHA64.9, WHA64.8, WHA63.27,WHA62.12 and WHA60.27); WHO’s role and responsibilities in health research (resolution WHA63.21); Global strategy and plan of action on public health, innovation and intellectual property (resolution WHA61.21)